RNA science is now translated into new therapies…
Last August, the FDA approved the first RNAi therapy, Onpattro®…
RNA drugs allow precised silencing or activation of genes…
RNA drugs can address a wide range of common and rare diseases…
More than 60 rare or common diseases are currently targeted….
BioPharmAnalyses and Octopusyx BioConsulting
are proud to announce the launch of the first issue of
« BRIEFING ON RNA TRIALS »
You need to get an update on the clinical portfolio of RNA products?
You need insights to assist you in your decision-making in RNA drugs?
You need to identify the most advanced companies?
You need to in-license a new candidate?
You need to identify licensed products ?
Briefing on RNA Trials is the up-dated report on RNA products you need to have.
It gives you an accurate overview
to explore the latest trials and publications in this dynamic area.
« BRIEFING ON RNA TRIALS » BY NUMBERS